AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Microbot Medical Inc.
Video analysis: MBOT
All videosNo video analysis for this stock yet. Request one from our team.
News: MBOT
Financial Analysis: Koninklijke Philips (NYSE:PHG) & Microbot Medical (NASDAQ:MBOT)
Koninklijke Philips (NYSE: PHG - Get Free Report) and Microbot Medical (NASDAQ: MBOT - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Insider and Institutional Ownership 13.7% of Koninklijke Philips
Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates
Microbot Medical Inc. (MBOT) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.1 per share a year ago.
Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter
Revenue increased by more than 100% over the prior fiscal quarter, driven by repeat orders, expanded utilization among existing customers, and the acquisition of new customers since the Full Market Release in mid-April The Company added new customers in Q3 while expanding into new states and sites of service HINGHAM, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026 with the Securities and Exchange Commission (SEC).
New Strong Buy Stocks for July 23rd
PLGO, BLPD, INN, RFIL and MBOT have been added to the Zacks Rank #1 (Strong Buy) List on July 23, 2026.
Microbot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual Meeting
HINGHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, will be participating at this year's Society of Robotic Surgery (SRS) annual meeting, being held from July 23-26, in Fort Lauderdale, FL.
Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026
The Company is experiencing rising demand and increasing pipeline for the LIBERTY System since commencing the Full Market Release in April Heightened awareness generating interest from leading health systems across the U.S. as Company plans to increase its U.S. sales territories from 8 to 12 and enter international markets by the end of 2026 HINGHAM, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, is reporting greater than 100% growth in revenue and new customers for the second quarter ended June 30, 2026, compared to the first quarter ended March 31, 2026.
Microbot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader
HINGHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, has entered into a Letter of Agreement (LOA) with Sanmina Corporation, a leading global integrated manufacturing solutions provider, to manufacture the LIBERTY System, the only FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures.
Microbot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System
HINGHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it has won the Innovative Start-Up Award from Surgical Robotics Technology (SRT), which recognizes companies with outstanding technological and commercial progress through highly innovative, groundbreaking technologies with the potential for broad healthcare impact.1 SRT, a leading platform for surgical robotics news, together with QNX, recognizes outstanding organizations, individuals, and technologies across the surgical robotics sector.
